Drug intelligence / Profile preview

KAT-002

Development stage: Preclinical
Lead developer: New G Lab Pharma
Modality: Small Molecules

Overview

KAT-002 is a small molecule anticancer therapeutic being developed by NewG Lab Pharma. It is part of the KoDiscovery Anticancer Therapeutics (KAT) pipeline, which focuses on targeting the Warburg Effect—a metabolic phenomenon where cancer cells preferentially utilize aerobic glycolysis for energy production even in the presence of oxygen. By inhibiting this metabolic pathway, KAT-002 aims to selectively disrupt the energy supply and biosynthetic requirements of malignant cells. The drug is currently in preclinical development, with its primary therapeutic focus directed toward the treatment of bladder cancer.

Beyond the preview

Go deeper on KAT-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAT-002.

Explore the full profile